Literature DB >> 9573231

Mutations in the human immunodeficiency virus type 1 integrase D,D(35)E motif do not eliminate provirus formation.

M Gaur1, A D Leavitt.   

Abstract

The core domain of human immunodeficiency virus type 1 (HIV-1) integrase (IN) contains a D,D(35)E motif, named for the phylogenetically conserved glutamic acid and aspartic acid residues and the invariant 35 amino acid spacing between the second and third acidic residues. Each acidic residue of the D,D(35)E motif is independently essential for the 3'-processing and strand transfer activities of purified HIV-1 IN protein. Using a replication-defective viral genome with a hygromycin selectable marker, we recently reported that a mutation at any of the three residues of the D,D(35)E motif produces a 10(3)- to 10(4)-fold reduction in infectious titer compared with virus encoding wild-type IN (A. D. Leavitt et al., J. Virol. 70:721-728. 1996). The infectious titer, as measured by the number of hygromycin-resistant colonies formed following infection of cells in culture, was less than a few hundred colonies per microg of p24. To understand the mechanism by which the mutant virions conferred hygromycin resistance, we characterized the integrated viral DNA in cells infected with virus encoding mutations at each of the three residues of the D,D(35)E motif. We found the integrated viral DNA to be colinear with the incoming viral genome. DNA sequencing of the junctions between integrated viral DNA and host DNA showed that (i) the characteristic 5-bp direct repeat of host DNA flanking the HIV-1 provirus was not maintained, (ii) integration often produced a deletion of host DNA, (iii) integration sometimes occurred without the viral DNA first undergoing 3'-processing, (iv) integration sites showed a strong bias for a G residue immediately adjacent to the conserved viral CA dinucleotide, and (v) mutations at each of the residues of the D,D(35)E motif produced essentially identical phenotypes. We conclude that mutations at any of the three acidic residues of the conserved D,D(35)E motif so severely impair IN activity that most, if not all, integration events by virus encoding such mutations are not IN mediated. IN-independent provirus formation may have implications for anti-IN therapeutic agents that target the IN active site.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9573231      PMCID: PMC109991          DOI: 10.1128/JVI.72.6.4678-4685.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro.

Authors:  A Engelman; R Craigie
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases.

Authors:  J Kulkosky; K S Jones; R A Katz; J P Mack; A M Skalka
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

3.  The N-terminal region of HIV-1 integrase is required for integration activity, but not for DNA-binding.

Authors:  M Schauer; A Billich
Journal:  Biochem Biophys Res Commun       Date:  1992-06-30       Impact factor: 3.575

4.  A mutation at one end of Moloney murine leukemia virus DNA blocks cleavage of both ends by the viral integrase in vivo.

Authors:  J E Murphy; S P Goff
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

5.  Structural implications of spectroscopic characterization of a putative zinc finger peptide from HIV-1 integrase.

Authors:  C J Burke; G Sanyal; M W Bruner; J A Ryan; R L LaFemina; H L Robbins; A S Zeft; C R Middaugh; M G Cordingley
Journal:  J Biol Chem       Date:  1992-05-15       Impact factor: 5.157

6.  Site-directed mutagenesis of HIV-1 integrase demonstrates differential effects on integrase functions in vitro.

Authors:  A D Leavitt; L Shiue; H E Varmus
Journal:  J Biol Chem       Date:  1993-01-25       Impact factor: 5.157

7.  Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding.

Authors:  F D Bushman; A Engelman; I Palmer; P Wingfield; R Craigie
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

8.  Identification of the catalytic and DNA-binding region of the human immunodeficiency virus type I integrase protein.

Authors:  C Vink; A M Oude Groeneger; R H Plasterk
Journal:  Nucleic Acids Res       Date:  1993-03-25       Impact factor: 16.971

9.  Mutational analysis of the integrase protein of human immunodeficiency virus type 2.

Authors:  D C van Gent; A A Groeneger; R H Plasterk
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

10.  Simian virus 40 minichromosomes as targets for retroviral integration in vivo.

Authors:  P M Pryciak; H P Müller; H E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

View more
  29 in total

1.  A model for studying megakaryocyte development and biology.

Authors:  G J Murphy; A D Leavitt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  Isolation and analysis of retroviral integration targets by solo long terminal repeat inverse PCR.

Authors:  Yi Feng Jin; Toshio Ishibashi; Akio Nomoto; Michiaki Masuda
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  Integrase-lexA fusion proteins incorporated into human immunodeficiency virus type 1 that contains a catalytically inactive integrase gene are functional to mediate integration.

Authors:  M L Holmes-Son; S A Chow
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  A high-throughput method for cloning and sequencing human immunodeficiency virus type 1 integration sites.

Authors:  Sanggu Kim; Yein Kim; Teresa Liang; Janet S Sinsheimer; Samson A Chow
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 5.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

6.  An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate.

Authors:  Benjamin Trinité; Eric C Ohlson; Igor Voznesensky; Shashank P Rana; Chi N Chan; Saurabh Mahajan; Jason Alster; Sean A Burke; Dominik Wodarz; David N Levy
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

7.  Measurement of human immunodeficiency virus type 1 preintegration transcription by using Rev-dependent Rev-CEM cells reveals a sizable transcribing DNA population comparable to that from proviral templates.

Authors:  Subashini R Iyer; Dongyang Yu; Angélique Biancotto; Leonid B Margolis; Yuntao Wu
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

8.  An unbiased genome-wide analysis of zinc-finger nuclease specificity.

Authors:  Richard Gabriel; Angelo Lombardo; Anne Arens; Jeffrey C Miller; Pietro Genovese; Christine Kaeppel; Ali Nowrouzi; Cynthia C Bartholomae; Jianbin Wang; Geoffrey Friedman; Michael C Holmes; Philip D Gregory; Hanno Glimm; Manfred Schmidt; Luigi Naldini; Christof von Kalle
Journal:  Nat Biotechnol       Date:  2011-08-07       Impact factor: 54.908

9.  Analysis of wild-type and mutant SL3-3 murine leukemia virus insertions in the c-myc promoter during lymphomagenesis reveals target site hot spots, virus-dependent patterns, and frequent error-prone gap repair.

Authors:  Anne Ahlmann Nielsen; Annette Balle Sørensen; Jörg Schmidt; Finn Skou Pedersen
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

10.  Long-term episomal transgene expression from mitotically stable integration-deficient lentiviral vectors.

Authors:  Hanna Kymäläinen; J Uwe Appelt; Frank A Giordano; Angela F Davies; Caroline M Ogilvie; Sherif G Ahmed; Stephanie Laufs; Manfred Schmidt; Juergen Bode; Rafael J Yáñez-Muñoz; George Dickson
Journal:  Hum Gene Ther       Date:  2014-04-10       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.